22 November 2021 ORYZON announces new Global Chief Business Officer and expansion of US corporate activities
17 November 2021 ORYZON enrolls first patient in EVOLUTION, a Phase IIb clinical trial with vafidemstat in schizophrenia
15 November 2021 ORYZON publishes paper in ACS Pharmacology & Translational Science supporting best-in-class performance of iadademstat in Oncology
9 November 2021 ORYZON to present new clinical data and corporate updates at international conferences in November and December
18 October 2021 ORYZON enrolls first patient in the US in PORTICO, a Phase IIb clinical trial with vafidemstat in Borderline Personality Disorder
13 October 2021 ORYZON presents safety and efficacy data of vafidemstat from the Phase II SATEEN trial in multiple sclerosis at ECTRIMS-2021
22 September 2021 ORYZON to present new clinical data and corporate updates at international conferences in September and October
21 September 2021 Oryzon announces $1 million grant from Kabuki syndrome philanthropists to support a precision medicine Phase I/II trial with vafidemstat